E-LIB Suche - Ergebnisse für: Saber, Haleh

1

Pharmacokinetic models for first-in-human dose selection of..:

Saber, Haleh ; Thompson, Matthew D. ; Leighton, John K.
Regulatory Toxicology and Pharmacology. 149 (2024) - p. 105616 , 2024

Link: https://doi.org/10.1016/..

2

Trends in the approval of cancer therapies by the FDA in th..:

Scott, Emma C. ; Baines, Andrea C. ; Gong, Yutao...
Nature Reviews Drug Discovery. 22 (2023) 8 - p. 625-640 , 2023

Link: https://doi.org/10.1038/..

3

An FDA analysis of clinical hold deficiencies affecting inv..:

Manning, Michael L. ; Thompson, Matthew D. ; Saber, Haleh...
Regulatory Toxicology and Pharmacology. 110 (2020) - p. 104511 , 2020

Link: https://doi.org/10.1016/..

4

An FDA oncology analysis of toxicities associated with PBD-..:

Saber, Haleh ; Simpson, Natalie ; Ricks, Tiffany K..
Regulatory Toxicology and Pharmacology. 107 (2019) - p. 104429 , 2019

Link: https://doi.org/10.1016/..

5

Clinical Development of Cancer Drugs in Combination With Ex..:

Walker, Amanda J. ; Kim, Hyun ; Saber, Haleh...
International Journal of Radiation Oncology*Biology*Physics. 98 (2017) 1 - p. 5-7 , 2017

Link: https://doi.org/10.1016/..

6

An FDA oncology analysis of CD3 bispecific constructs and f..:

Saber, Haleh ; Del Valle, Pedro ; Ricks, Tiffany K..
Regulatory Toxicology and Pharmacology. 90 (2017) - p. 144-152 , 2017

Link: https://doi.org/10.1016/..

7

An FDA oncology analysis of immune activating products and ..:

Saber, Haleh ; Gudi, Ramadevi ; Manning, Michael..
Regulatory Toxicology and Pharmacology. 81 (2016) - p. 448-456 , 2016

Link: https://doi.org/10.1016/..

8

An FDA oncology view of juvenile animal studies in support ..:

Leighton, John K. ; Saber, Haleh ; Reaman, Gregory.
Regulatory Toxicology and Pharmacology. 79 (2016) - p. 142-143 , 2016

Link: https://doi.org/10.1016/..

9

An FDA oncology analysis of antibody-drug conjugates:

Saber, Haleh ; Leighton, John K.
Regulatory Toxicology and Pharmacology. 71 (2015) 3 - p. 444-452 , 2015

Link: https://doi.org/10.1016/..

10

U.S. Food and Drug Administration Approval Summary: Omaceta..:

Alvandi, Firoozeh ; Kwitkowski, Virginia E. ; Ko, Chia-Wen...
The Oncologist. 19 (2013) 1 - p. 94-99 , 2013

Link: https://doi.org/10.1634/..

11

U.S. Food and Drug Administration Approval Summary: Omaceta..:

Alvandi, Firoozeh ; Kwitkowski, Virginia E ; Ko, Chia-Wen...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC. , 2014

Link: http://www.ncbi.nlm.nih...

12

Effects of functional group position on spatial representat..:

Johnson, Brett A. ; Farahbod, Haleh ; Saber, Sepideh.
The Journal of Comparative Neurology. 483 (2005) 2 - p. 192-204 , 2005

Link: https://doi.org/10.1002/..

13

Local and global chemotopic organization: General features ..:

Johnson, Brett A. ; Farahbod, Haleh ; Xu, Zhe..
Journal of Comparative Neurology. 480 (2004) 2 - p. 234-249 , 2004

Link: https://doi.org/10.1002/..

14

Role of Nongovernmental Organizations in Controlling COVID-..:

Mohseni, Mohammad ; Azami-Aghdash, Saber ; Mousavi Isfahani, Haleh..
Disaster Medicine and Public Health Preparedness. 16 (2021) 5 - p. 1705-1705 , 2021

Link: https://doi.org/10.1017/..

15

Development of quality indicators to measure pre-hospital e..:

Azami-Aghdash, Saber ; Moosavi, Ahmad ; Gharaee, Hojatolah...
BMC Health Services Research. 21 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..